Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/17446
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Author: Chapman, I.
Parker, B.
Doran, S.
Feinle-Bisset, C.
Wishart, J.
Strobel, S.
Wang, Y.
Burns, C.
Lush, C.
Weyer, C.
Horowitz, M.
Citation: Diabetologia, 2005; 48(5):838-848
Publisher: Springer
Issue Date: 2005
ISSN: 0012-186X
1432-0428
Statement of
Responsibility: 
I. Chapman, B. Parker, S. Doran, C. Feinle-Bisset, J. Wishart, S. Strobel, Y. Wang, C. Burns, C. Lush, C. Weyer and M. Horowitz
Abstract: Long-term trials in insulin-treated subjects with type 2 diabetes have shown that adjunctive treatment with the amylin analogue pramlintide reduces HbA(1)c levels and elicits weight loss. While amylin reduces food intake in rodents, pramlintide's effect on satiety and food intake in humans has not yet been assessed.In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests. After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal. After 1 h, subjects ate an ad libitum buffet meal. Energy intake and meal duration were measured, as were hunger ratings (using visual analogue scales), and plasma cholecystokinin, glucagon-like peptide-1 and peptide YY concentrations over time.Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration. Hunger and hormonal analyte profiles provided evidence that pramlintide may exert a primary satiogenic effect, independently of other anorexigenic gut peptides.The results indicate that enhanced satiety and reduced food intake may explain the weight loss observed in long-term pramlintide trials.
Keywords: Amylin; Hunger; Obesity; Peptide hormones; Satiety
Description: The original publication is available at www.springerlink.com
Rights: © Springer-Verlag 2005
RMID: 0020050193
DOI: 10.1007/s00125-005-1732-4
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.